Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma

Clinical trial NCT05226494 · RECRUITING

Trial details

NCT number: NCT05226494
Sponsor: NanoPharmaceuticals LLC
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Glioma, Malignant

Start date: 2022-06-23
Primary completion: 2026-10-01
Enrollment: 34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.